{"doi":"10.1016/j.celrep.2020.108274","title":"An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain","abstract":"IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 because of structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing antibodies here demonstrate that a longer CDR H3 can be accommodated in a different binding mode (mode B). These two classes of IGHV3-53 antibodies both target the ACE2 receptor binding site, but with very different angles of approach and molecular interactions. Overall, these findings emphasize the versatility of IGHV3-53 in this common antibody response to SARS-CoV-2, where conserved IGHV3-53 germline-encoded features can be combined with very different CDR H3 lengths and light chains for SARS-CoV-2 RBD recognition and virus neutralization.","journal":"Cell Reports","year":2020,"id":50433,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":194,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9514,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":105423,"name":"Meng Yuan","orcid":"0000-0001-9754-4503","position":1,"is_corresponding":false},{"id":108970,"name":"Hejun Liu","orcid":null,"position":2,"is_corresponding":false},{"id":105426,"name":"Chang‐Chun D. Lee","orcid":"0000-0002-5470-2484","position":3,"is_corresponding":false},{"id":105425,"name":"Xueyong Zhu","orcid":"0000-0002-6021-3740","position":4,"is_corresponding":false},{"id":230740,"name":"Sandhya Bangaru","orcid":"0000-0001-7994-4693","position":5,"is_corresponding":false},{"id":106545,"name":"Jonathan L. Torres","orcid":"0000-0003-0137-8497","position":6,"is_corresponding":false},{"id":240714,"name":"Tom G. Caniels","orcid":"0000-0001-9580-157X","position":7,"is_corresponding":false},{"id":240716,"name":"Philip J. M. Brouwer","orcid":"0000-0002-2902-7739","position":8,"is_corresponding":false},{"id":240717,"name":"Marit J. van Gils","orcid":"0000-0003-3422-8161","position":9,"is_corresponding":false},{"id":240718,"name":"Rogier W. Sanders","orcid":"0000-0002-2324-8573","position":10,"is_corresponding":false},{"id":106561,"name":"Andrew B. Ward","orcid":null,"position":11,"is_corresponding":false},{"id":105430,"name":"Ian A. Wilson","orcid":"0000-0002-6469-2419","position":12,"is_corresponding":false},{"id":105424,"name":"Nicholas C. Wu","orcid":"0000-0002-9078-6697","position":0,"is_corresponding":true}],"reference_count":42,"raw_metadata":null,"created_at":"2026-07-18T20:38:25.860949Z","pmid":"33027617","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}